Clinical Trial Update: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission [Phase 2]

View source ↗

Summary

This is a Phase 2 trial of vismodegib as maintenance therapy in ovarian cancer patients in second or third complete remission. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-04-26